 |
|
|
| |
Primary Data Analyses of MAESTRO-NAFLD-1:a 52-week
Double-blind, Placebo-controlled Phase 3 Clinical
Trial of Resmetirom in Patients With NAFLD
|
| |
| |
EASL 2022 June 22-26 London
Stephen A. Harrison,1 Rebecca A. Taub,2 Guy W. Neff,3 Sam Moussa,4 Naim Alkhouri,5 Mustafa R. Bashir6
1University of Oxford, UK; Pinnacle Clinical Research, San Antonio, TX, USA; 2Madrigal Pharmaceuticals, Conshohocken, PA, USA; 3Covenant Metabolic Specialists, Sarasota, FL, USA; 4University of Arizona College of Medicine, Tucson, AZ, USA; 5Arizona Liver Health, Tucson AZ, USA; 6Duke University Medical Center, Durham, NC, USA
|
| |
|
|
|
|
|
